Author: toxlaw

A reduced response to a later methamphetamine exposure does not necessarily mean the nervous system has returned to its original state. In a 2012 rat experiment, prior methamphetamine self-administration was associated with persistent changes in dopamine-transporter function while also reducing several effects of a subsequent high-dose exposure.

That combination is scientifically coherent. Tolerance describes a change in a specified response to a specified exposure. It does not, by itself, mean normal function across every biological endpoint. McFadden and colleagues’ study shows why the response, measurement and comparison group must travel with the word.

What exposure did the rats control?

This historical primary study used male Sprague-Dawley rats. Animals could earn intravenous methamphetamine during eight-hour sessions on seven consecutive days. Experiments used 0.06, 0.12 or 0.24 mg per infusion, with doses described as methamphetamine free base. These were amounts per infusion, not mg/kg doses.

The authors distinguished high-pressing rats using both an average of more than ten active lever presses per day and an active-to-inactive response ratio of at least two to one. Many later analyses concentrated on that subgroup. It should not be treated as a representative sample of all exposed rats or all people using methamphetamine.

The study contained several experiments, rather than one cohort supplying every result. Group sizes, sampling times and comparison conditions therefore differed between endpoints.

What persisted after self-administration ended?

With the 0.06 mg-per-infusion regimen, striatal dopamine-transporter uptake function was reduced eight days after the final session in the high-pressing animals. The functional comparison included ten saline controls, four low-pressing methamphetamine rats and twenty-one high-pressing methamphetamine rats.

A separate experiment found a reduction in transporter function thirty days after the final session. That comparison was small and unbalanced: three saline controls and nine high-pressing methamphetamine rats. It supports persistence to that observation point under this protocol, not an indefinite duration or a precise estimate for human recovery.

At thirty days, transporter protein immunoreactivity, dopamine content, tyrosine hydroxylase immunoreactivity and the astrocytic marker GFAP did not show statistically significant group differences. The functional transporter result therefore should not be rewritten as a demonstrated loss of the same proportion of neurons.

Did a higher infusion dose simply produce a larger deficit?

No simple linear pattern emerged across all measurements. Increasing the amount per infusion increased total intake, but transporter alterations were not uniformly larger across the tested regimens. At 0.24 mg per infusion, striatal dopamine content was reduced at the eight-day assessment; lower infusion doses did not produce that significant dopamine-content result.

Function, protein abundance and tissue dopamine are related measurements, but they answer different questions. A null result for one does not erase a difference in another. Conversely, a transporter difference does not establish that every dopamine-system measure was abnormal.

What happened during the later high-dose challenge?

For the challenge experiment, rats first self-administered 0.12 mg per infusion, or saline, during the seven-day schedule. The later investigator-administered regimen comprised four subcutaneous methamphetamine injections of 7.5 mg/kg each, separated by two hours. It began twenty-four hours after the beginning of the final self-administration session.

Seven days after that challenge, animals with prior methamphetamine self-administration showed smaller changes in several striatal endpoints than saline-pretreated animals given the same challenge. These included transporter uptake, transporter protein measurements, GFAP and dopamine content. The main comparison involved seven saline/saline, fourteen methamphetamine/methamphetamine and eleven saline/methamphetamine animals; denominators varied for some assays.

The appropriate comparison is attenuation relative to a previously saline-exposed challenge group. It is not proof that prior exposure restored every endpoint to baseline. The tyrosine hydroxylase analysis in this experiment did not reach statistical significance, with p=0.08, and should not be listed as an independently significant protective finding.

Could lower drug concentrations explain the result?

One hour after the final challenge injection, the investigators measured methamphetamine and amphetamine in brain tissue. Reported methamphetamine means were 7.77 ± 0.62 ng/mg wet weight after saline pretreatment and 9.09 ± 0.97 ng/mg after methamphetamine pretreatment. The corresponding amphetamine means were 2.21 ± 0.18 and 2.59 ± 0.15 ng/mg. Values were means ± standard errors; neither analyte comparison was statistically significant.

These were brain-tissue concentrations, not blood concentrations or impairment thresholds. They did not support lower brain exposure at that sampling time as the explanation for attenuation. A nonsignificant comparison at one time point also does not establish pharmacokinetic equivalence throughout the challenge.

What remains unresolved?

Prior self-administration reduced the early hyperthermic response to the challenge. Housing animals in a warmer environment did not eliminate that temperature difference, so the authors considered altered thermoregulation a likely contributor. The study did not isolate a single exclusive protective mechanism.

Its larger interpretive contribution is that persistent alteration and reduced sensitivity to a later challenge can coexist. Neither a tolerance label nor an apparently smaller later deficit demonstrates overall safety, clinical benefit or resistance to impairment. The study measured selected rat brain endpoints under a particular sequence of exposures; it did not establish a human protective treatment or a method for interpreting a driver’s toxicology result.

References

McFadden LM, Hadlock GC, Allen SC, et al. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. Journal of Pharmacology and Experimental Therapeutics. 2012;340(2):295–303. doi:10.1124/jpet.111.188433. Historical primary rat research.

Finding an antibody after repeated drug exposure does not show that the exposure has vaccinated an animal against harm. In a 2007 experiment, Treweek and colleagues used the term “self-vaccination” for an immune response associated with methamphetamine-modified proteins. The result concerned recognition of altered proteins, not demonstrated protection from intoxication, dependence or cardiovascular disease.

The paper presents a chemical and immunological hypothesis worth understanding on its own terms. Its most useful distinction is between detecting an immune response, identifying the molecular material that response recognizes, and showing that the response causes a particular disease. Those are separate evidentiary steps.

What was actually studied?

This was historical primary research using male Wistar rats and laboratory assays, not a clinical study of people using methamphetamine. After six baseline training sessions, rats had either one hour or six hours of daily access to intravenous methamphetamine. Each earned infusion delivered 0.05 mg/kg. The escalation period lasted at least 87 days.

Blood was collected from four drug-naive rats, ten short-access rats and thirteen long-access rats. Those group sizes describe the sampled animals; they are not human patient denominators. Samples came from animals used in two separate studies, which matters when considering comparability and the small drug-naive reference group.

The long-access animals reportedly averaged approximately 7 mg/kg over a six-hour session. That is cumulative intake during the session, not the dose in a single infusion. The paper’s comparisons with human exposure were interpretive arguments; the rat daily intake should not be converted into a human dose or a safety boundary.

What does protein glycation mean here?

The investigators considered whether methamphetamine could participate in reactions producing modified proteins, described as methamphetamine advanced glycation end products, or methamphetamine AGEs. They prepared modified mouse and rat serum albumin in the laboratory and used those materials to test antibody binding in the animals’ samples.

An ELISA measured binding to the prepared antigens. The study reported stronger antibody signals with greater methamphetamine intake, and antibodies from long-access rats recognized modified albumin derived from both rats and mice more strongly than samples from drug-naive animals.

This was not an assay measuring the concentration of unchanged methamphetamine in a driver’s blood. Its output concerned antibody recognition under specified laboratory conditions. It also was not a validated clinical test identifying the dose, timing or consequences of an individual’s drug use.

Why is “self-vaccination” easy to misread?

Vaccination commonly suggests a beneficial immune response deliberately induced to prevent an illness. Here, the authors used the concept to describe repeated exposure generating antibodies without an added vaccine adjuvant. They were investigating potentially harmful immunological consequences, not showing that methamphetamine use protected the animals.

The experiment did not establish that these antibodies reduced brain exposure to methamphetamine, prevented drug taking, or improved cardiovascular health. Nor did it compare a therapeutic methamphetamine vaccine with placebo. Those claims would require different experiments and outcomes.

Which immune signals changed?

The paper also examined circulating cytokines and chemokines using an antibody array. Relative to the drug-naive group, long-access samples showed approximately fivefold higher TNF-alpha and sixfold higher vascular endothelial growth factor, or VEGF. Short-access samples showed approximately twofold higher VEGF.

The pattern was not a uniform increase across all immune signals. IL-1beta was lower with short access but higher with long access, while an observed reduction in interferon-gamma with short access was not maintained with longer access. Preserving those differences matters: “immune activation” is too broad to capture every measured response.

The reported fold changes were comparisons with the reference group’s assay signals. They were not the percentage of animals developing disease, absolute clinical cytokine thresholds, or estimates of a person’s future cardiovascular risk.

Did the experiment establish a cardiovascular mechanism?

The authors proposed that modified proteins and associated inflammatory signals could help explain vascular consequences of chronic methamphetamine exposure. They discussed earlier AGE research and clinical observations to build that hypothesis.

However, the rat measurements reported here did not establish a chain in which a measured amount of methamphetamine AGE caused a measured amount of arterial injury and then a clinical cardiovascular event. Antibody titers, exposure patterns and cytokine signals moving together do not by themselves identify which factor caused another.

A stronger causal test would need to distinguish the consequences of glycation and antibody recognition from other effects of repeated methamphetamine exposure. In particular, directly altering the proposed pathway and measuring vascular outcomes would answer a different question from comparing immune signals after different access schedules.

How should this paper be used in a case review?

The defensible description is that this small animal study supplied evidence of antibody recognition and altered peripheral immune signals after prolonged methamphetamine self-administration. It generated a proposed mechanism linking chronic exposure with vascular pathology.

It cannot establish that a particular person’s positive methamphetamine result represents the same immune process, that antibodies protected that person, or that this pathway caused that person’s illness. An opinion should identify the species, exposure duration, laboratory endpoint and untested causal steps before relying on the paper’s more expansive title.

References

Treweek J, Wee S, Koob GF, Dickerson TJ, Janda KD. Self-vaccination by methamphetamine glycation products chemically links chronic drug abuse and cardiovascular disease. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(28):11580–11584. doi:10.1073/pnas.0701328104. Historical primary animal and laboratory research.

Postmortem bilirubin measurements can add biochemical context to a death investigation, but a correlated result is not necessarily an interchangeable result. In a 37-case study, cardiac serum missed three of six elevated emergency-department values, while pericardial fluid had lower concentrations and did not significantly distinguish cirrhosis cases from controls. The study did not validate bilirubin as a measure of drug clearance or proof of drug-induced liver injury.

Which earlier results were available?

Takasu, Matsumoto and Sakamoto retrospectively studied forensic autopsies performed at one Japanese center from December 2021 through June 2023. Inclusion required postmortem serum and pericardial-fluid total bilirubin results and emergency-department biochemical data.

The 37 cases included 29 males and eight females, aged 13–87 years, with postmortem intervals of 14–67 hours. All had arrived at the emergency department in cardiopulmonary arrest and received resuscitation. The paper called the emergency-department results “antemortem”; these should not be mistaken for routine healthy outpatient baselines.

Postmortem pericardial fluid was collected through a pericardial incision using a sterile syringe. Serum came from cardiac blood obtained during heart excision, not femoral blood. Specimens were transferred to a laboratory and stored at −80°C; the maximum collection-to-transfer period was three days.

A strong serum correlation still missed individual elevations

Total bilirubin was measured by an oxidation method. Antemortem and postmortem serum concentrations had a Spearman correlation of 0.83, and the paired comparison showed no significant group difference.

However, six cases had emergency-department values above the paper’s living-person reference interval of 0.3–1 mg/dL. Three of those six had postmortem serum results below that interval’s upper boundary. One other case changed from 0.9 mg/dL before death to 1.1 mg/dL afterward.

Thus, a nonsignificant group comparison did not mean that every individual retained the same classification. The discussion once labels the missed elevations “false positives,” but the case table and results identify them as false negatives. That wording inconsistency should not reverse the actual direction of the changes.

Pericardial fluid answered a different specimen question

Pericardial-fluid total bilirubin correlated with the earlier serum result, with Spearman’s coefficient 0.57, but concentrations were significantly lower. The reported fluid-to-earlier-serum ratio was 0.41 ± 0.27 after excluding one case whose earlier value was zero.

The abstract describes this as a median accompanied by a variation term, while the presentation elsewhere does not clearly resolve that summary convention. It is safer to preserve it as the paper’s reported ratio summary rather than invent a uniform conversion.

The investigators also fitted a regression equation. That fit within a small selected dataset was not independent validation of an individual prediction rule, and the report did not provide a validated prediction interval for a new case. Dividing a pericardial result by 0.41 would not create a measured serum concentration.

The cirrhosis comparison had only three affected cases

There were three cirrhosis cases and 34 controls. Serum total bilirubin was significantly higher in cirrhosis both before death and postmortem, with p = 0.0067 and p = 0.037, respectively. Pericardial fluid showed no significant difference, with p = 0.37.

Median pericardial values were 0.10 mg/dL in cirrhosis and 0.20 mg/dL in controls. These results did not establish a diagnostic pericardial threshold. The proposed explanation of dilution was not confirmed: fluid volume also did not differ significantly between groups.

The difference between earlier and postmortem serum bilirubin did not correlate significantly with postmortem interval, with p = 0.65. Within 37 cases and a 14–67-hour interval, that null result cannot establish stability during longer delays or advanced decomposition.

Why this does not measure drug metabolism

The authors acknowledged possible storage effects and did not analyze prescription-related influences because the available medication data were insufficient. The report did not reproduce numerical analytical detection limits, quantitation limits or imprecision estimates for these specimens.

Bilirubin is a biochemical measurement, not identification or quantification of a toxicant. This study cannot establish that a drug impaired liver function, quantify a decedent’s hepatic elimination capacity, or correct an autopsy drug concentration to its antemortem value.

Its practical contribution is to keep specimen, clinical context, individual discordance and diagnostic performance together. A similar distinction between correlation and substitution appears in pericardial diazepam and blood comparisons. Detection of a drug or an abnormal biochemical marker remains separate from an integrated cause-of-death assessment.

Primary source

Takasu S, Matsumoto S, Sakamoto K. A Comparison of Postmortem Serum and Pericardial Fluid Total Bilirubin Levels With Antemortem Data. Cureus. 2025;17(2):e79089. doi:10.7759/cureus.79089.

A measured nitrous oxide concentration from a living driver cannot simply be used as a reference boundary for an autopsy. A Danish study detected the gas in 52 of 62 selected traffic-case blood samples, but reported positive cases qualitatively because the total loss before analysis was unknown. Its findings establish testing feasibility under a specified workflow, rather than a validated scale of impairment or fatality.

A living-person study with a selected denominator

Lindholm and colleagues retrospectively reviewed all traffic-case samples specifically requested for nitrous oxide analysis in Eastern Denmark from 1 January 2020 through 31 December 2022. The 62 cases were selected because police suspected recent exposure. They were not a random sample of drivers or autopsy cases.

Fifty-seven drivers were male and five female. Ages ranged from 15 to 37 years, with a median of 22. Sixty cases came from Greater Copenhagen and two from rural Zealand. A rising number of requests could reflect changing suspicion or testing practice as well as changing exposure.

The 52 positive cases, or 84%, therefore describe this referred group. The percentage is neither population prevalence nor a validation sensitivity estimate: the study did not independently establish the exposure status of every negative case.

How the specimens were handled

Medical staff drew blood into 5 mL tubes containing 12.5 mg sodium fluoride and 10 mg potassium oxalate. Samples reached the laboratory within a few days and were stored at −20°C or colder until analysis. The report did not establish one fixed exposure-to-draw interval or one anatomical collection site for all cases.

The assay transferred 500 µL of blood to a headspace vial, sealed it immediately, and added xenon gas as the internal standard. HS-GC–MS analysis used freshly prepared aqueous calibrators at 0.1, 0.2, 1.0 and 10 mL/L, with quality controls before and after the case samples. Specimens were tested in duplicate.

Using the m/z 30 fragment for nitrous oxide reduced interference from carbon dioxide. This is a method-specific analytical choice; it does not establish that every mass-spectrometric nitrous oxide procedure has equivalent selectivity or sensitivity.

Calculated concentrations and qualitative reports were different

The positive samples had calculated concentrations reported as 0.1–48 mL nitrous oxide per L of blood. The laboratory defined a positive result as a duplicate mean above 0.1 mL/L and issued the result as “detected.” The rounded lower endpoint should not erase the stated above-cutoff rule.

The threshold produced a response approximately ten times the atmospheric background response in this method. It was a reporting choice for evidence of exposure, not an experimentally determined concentration at which driving performance becomes unsafe.

Although calibration produced numerical values, the authors deliberately limited the case reporting. Biological elimination, storage and opening the original tubes for transfer could all reduce the amount measured. The magnitude of their combined contribution remained unknown.

Why the numbers cannot be back-calculated

A fixed multiplier cannot recover the concentration at police apprehension from these results. The study did not establish individual elimination curves or quantify each specimen’s loss. A low measured value consequently does not measure the intensity of an earlier effect, and a negative result cannot precisely date or exclude every earlier exposure.

After death, the sampling context changes further. The living-driver dataset contains ongoing physiological elimination before collection, while autopsy specimens involve different sites, intervals and handling. The authors’ discussion of previously published deaths was not a paired living-to-postmortem experiment within these 62 cases.

The broader specimen lesson also appears in hospital ethanol specimens used in death investigations: retain the original matrix and timing rather than silently treating unlike results as interchangeable.

Co-detected drugs did not establish simultaneous intake

Only eight cases underwent blood-alcohol testing; three were positive. Fifty-two underwent testing for other traffic-impairing drugs, and 26 had findings above the study’s stated legal-limit criteria. These denominators are different from the 52 nitrous-oxide-positive samples. The study’s historical Danish classification should not be presented as a legal rule for another jurisdiction.

Neither the co-findings nor the nitrous oxide measurement alone established a specific drug combination’s contribution to driving behavior, a crash or a death. The useful conclusion is that targeted detection was possible in ordinary whole-blood samples, with substantial limits on quantitative reconstruction and postmortem extrapolation.

Primary source

Lindholm AØ, Nielsen MKK, Kristensen M, Rasmussen BS. Driving under the influence of nitrous oxide – A retrospective study of HS-GC-MS analysis in whole blood. Forensic Science International. 2024;354:111904. doi:10.1016/j.forsciint.2023.111904.

Measuring nitrous oxide after death requires more than finding a mass-spectrometric peak shared with carbon dioxide. Li and colleagues developed a blood method that removed interfering carbon dioxide and then applied it to two suspected fatal poisonings. The measured heart-blood concentrations and positive tissue findings supported the investigations, but did not establish a universal lethal range or quantitative validation for every specimen.

Why the identification problem mattered

Nitrous oxide and carbon dioxide share the same nominal molecular mass. In this study, the selected chromatographic column did not completely separate them, even at relatively low carbon dioxide concentrations. A signal at mass-to-charge ratio 44 therefore could not, by itself, resolve the analytical problem.

The investigators used sodium hydroxide treatment to remove carbon dioxide and headspace gas chromatography–mass spectrometry, or HS-GC–MS, to analyze the remaining gas. Identification compared retention time with a reference within 1% and evaluated ions at m/z 44, 30 and 28 and their relative abundances. Quantification used m/z 30 for nitrous oxide and n-pentane as the internal standard.

These were defined identification criteria and a separate quantitative calculation. A reference match, an instrument response and an accurately measured concentration are related but distinct parts of the evidence.

What blood performance was demonstrated?

The study evaluated eight blank human blood samples and eight blood samples with internal standard. It reported a blood calibration range of 0.02–0.5 mL nitrous oxide per mL of blood, with R² above 0.995. The adopted detection limit was 0.005 mL/mL and the quantitation limit was 0.02 mL/mL.

The detection limit was practical rather than the lowest visible signal: lower levels created unacceptable operational variation during manual gas dilution. The quantitation limit also reflected the practical precision of the gas syringes. Neither limit is a biological threshold for impairment or poisoning.

Accuracy and precision were tested at 0.06, 0.2 and 0.4 mL/mL, using six replicates per level over four nonconsecutive days. Reported bias ranged from −7.6% to +4.9%; intraday relative standard deviations ranged from 4.3% to 10.4%, and interday values from 7.0% to 8.8%.

Collection was part of the analytical procedure

During the two autopsies, blood, tissues and urine were placed directly into prepared headspace bottles and immediately sealed. Lung and stomach gas was collected using a gas-tight syringe and transferred to gas collection bags. Specimens were returned promptly to the laboratory and tested immediately.

The paper did not provide a uniform death-to-autopsy interval, a controlled delayed-storage experiment, or a paired antemortem comparison. Its successful application therefore does not validate arbitrary transport delays, repeatedly opened containers or reconstruction of the concentration during life.

What the two cases contributed

Heart blood contained 0.034 mL/mL in the first case and 0.14 mL/mL in the second. These were cardiac specimens, not femoral blood. The investigators also reported nitrous oxide in other biological specimens, including tissues and collected gases.

The method’s quantitative validation was expressly limited to human blood. Positive findings in lung, kidney, brain or other specimens did not become validated tissue concentrations merely because the same instrument detected them. The authors identified extension to other matrices as future work.

Two fatal cases can provide reference observations, but cannot establish the concentration separating survival from death. Detection does not independently quantify oxygen deprivation, establish the administered dose or prove an earlier period of impairment. Cause-of-death assessment still requires the complete investigation.

The method had acknowledged limitations

The authors noted possible loss of nitrous oxide through dissolution in the sodium hydroxide solution. They also acknowledged lower sensitivity than a previously published method reporting in mL/L. Units must be aligned: 0.005 mL/mL equals 5 mL/L, not 0.005 mL/L.

When reviewing a result, retain the blood site, sealing and transfer history, calibration units, identity criteria and validated matrix. The same need to examine analyte-specific scope appears in validation of a targeted 82-drug blood assay. Instrument capability alone does not establish every downstream interpretation.

Primary source

Li Z, Li Z, Qiang H, Xie W, Su M, Xiang P, Shi Y. Quantitative determination of nitrous oxide in human blood by HS-GC–MS: forensic application of two fatal poisoning cases. Forensic Science International. 2024;360:112067. doi:10.1016/j.forsciint.2024.112067.

A change in a brain-signaling protein is not a diagnosis of addiction or a measurement of impairment. A 2008 review described experiments linking extracellular signal-regulated kinases, or ERKs, to selected amphetamine and methamphetamine responses in animals. Those experiments helped test mechanisms of behavior and learning, but did not establish an individual human biomarker or treatment.

The distinction matters whenever a mechanistic finding is translated into a broader claim. Molecular activation, increased movement, learned place preference and compulsive drug taking are different observations.

What does “ERK activation” mean?

Lee and Messing described ERK1 and ERK2 as protein kinases involved in many ordinary cellular functions, including neuronal survival and synaptic plasticity. In the reviewed experiments, activation was commonly assessed by increased phosphorylated ERK, abbreviated p-ERK, in selected brain regions.

Phosphorylation is a chemical modification of a protein. A p-ERK measurement is therefore neither an amphetamine concentration nor a count of damaged neurons. Its meaning depends on the tissue, collection time, exposure and assay.

The review described amphetamine-related increases in p-ERK in several regions, including the ventral tegmental area and striatum. It did not establish a human p-ERK threshold separating ordinary exposure, intoxication, dependence or safe performance.

Why do inhibitor experiments add information?

A molecular change occurring after a drug is an association. Investigators can test its functional role by interfering with an upstream pathway and observing whether a defined outcome changes.

The reviewed work used inhibitors of MEK, an upstream activator of ERK, including SL327, U0126 and PD98059. Blocking an upstream step is not identical to directly and selectively inhibiting every function of ERK.

The review reported that systemic SL327 pretreatment reduced acute hyperlocomotion induced by amphetamine or methamphetamine in rodents. Other experiments linked MEK inhibition to reduced development of amphetamine-related psychomotor sensitization.

These findings support a role for the pathway in the tested responses. They do not establish that all drug effects were blocked, that the animals lacked every rewarding response, or that a clinically tolerable treatment was identified.

Is sensitization the same as addiction?

In these experiments, psychomotor sensitization meant a larger locomotor or repetitive-movement response after repeated exposure. It was a defined behavioral adaptation, not a comprehensive assessment of compulsive use despite harm.

A pathway needed for increased movement may participate in addiction-related processes without being sufficient to explain the entire disorder. Conversely, the absence of an observed sensitization effect does not prove absence of dependence or other drug-related risk.

The relevant denominator also remains the number of independent animals. Repeated injections, tissue measurements and observation intervals cannot be substituted for that count. The review did not provide one uniform cohort size or one standard dose-and-route protocol for all ERK experiments; those details require the individual primary reports.

What did conditioned place preference test?

Conditioned place preference measures an animal’s later choice between environments previously paired with drug or vehicle. The review described experiments in which systemic or brain-region-specific MEK inhibitor administration interfered with development of methamphetamine-related place preference.

That outcome concerns a learned drug–environment association. It is different from choosing to self-administer a drug, reporting euphoria or maintaining abstinence in clinical care.

Timing is essential. An intervention given during conditioning asks about learning or acquisition. An intervention given after an association is established asks a different question. Calling both “blocking addiction” would discard the actual experimental distinction.

Did memory-reconsolidation experiments erase addiction?

No such conclusion follows. The review discussed evidence that an established drug-associated memory can become temporarily modifiable when retrieved. It described MEK inhibition affecting later expression of methamphetamine place preference after a retrieval-related intervention.

The review also discussed cocaine experiments in which the retrieval condition mattered: inhibitor administration without the prior test that retrieved the association did not produce the same later deficit. That cocaine comparison helps explain the experimental logic, but should not be relabeled as a methamphetamine result.

A deficit in later preference does not independently establish permanent memory erasure, elimination of all drug-related learning or prevention of human relapse.

Why are ERK1 and ERK2 distinctions important?

The review noted that commonly used MEK inhibitors did not distinguish the two ERK isoforms. It also described ERK1-knockout mice with increased ERK2 signaling and enhanced cocaine-related sensitization or preference in some experiments.

Those knockout observations concerned cocaine and other specified drugs, not proof of the same response to amphetamine. They nevertheless illustrate why “less ERK” is an inadequate description: removing one component may produce compensation elsewhere in the pathway.

A lifelong genetic deletion, an acute systemic inhibitor and a small infusion into a particular brain region are different interventions. Their results cannot be treated as interchangeable replications.

What did the review conclude about treatment development?

The authors regarded protein-kinase pathways as research targets, while emphasizing that ERK and several other kinases serve many functions. Broad inhibition could therefore affect processes beyond the desired behavioral endpoint. They also highlighted difficulties with inhibitor specificity and interactions among signaling pathways.

These were historical drug-development considerations, not evidence that a MEK inhibitor was a proven treatment for amphetamine or methamphetamine use disorder. The reviewed animal outcomes did not supply a human benefit–risk estimate.

The defensible conclusion is narrower: ERK-related signaling contributed to selected drug-induced behaviors and learned associations under particular experimental conditions. It cannot establish an individual’s diagnosis, drug concentration, impairment or cause of an event.

Scientific source

Lee AM, Messing RO. Protein Kinases and Addiction. Annals of the New York Academy of Sciences. 2008;1141:22–57. doi:10.1196/annals.1441.022. Full-text author manuscript. Historical narrative review, with emphasis here on its ERK experiments and drug-target-development discussion. Primary experiments are described through the review rather than represented as independently reviewed original reports.

Chest-cavity fluid can provide a measurable cannabinoid metabolite when conventional specimens are difficult to obtain, but its THC-COOH concentration is not an interchangeable blood concentration or a clock for cannabis use. A 15-case autopsy study found THC-COOH in every chest-fluid specimen while leaving substantial uncertainty about specimen origin, postmortem change and quantitative interpretation.

Which cases and collection sites were studied?

Zughaibi and colleagues examined 15 selected cannabinoid-positive postmortem cases from Jeddah, Saudi Arabia, involving drug-related fatalities or criminal investigations. Fourteen decedents were male and one female; ages ranged from 18 to 50 years. The reported median postmortem interval was 48 hours, with case-table intervals from 24 to 320 hours.

Five cases were classified as non-putrefied, three partially putrefied and seven heavily decomposed. This was a selected case series, not a study of all deaths or all cannabis users. Thirteen cases involved other drugs.

Blood preserved with 1–2% sodium fluoride was collected from the subclavian vein, not the femoral vein. The text describes fluid from the chest or pleural cavity, but a figure caption also refers to chest and/or abdominal cavity fluid. That inconsistency limits how uniformly the fluid’s anatomical origin can be described. A pooled cavity specimen should not silently be relabeled peripheral blood.

What was measured in the chest fluid?

The investigators used solid-phase extraction followed by LC–MS/MS with labeled internal standards. THC-COOH was detected in all 15 cavity-fluid specimens, with a median of 480 ng/mL. Neither THC nor 11-hydroxy-THC was detected in that fluid.

The principal results give a THC-COOH range of 80–3010 ng/mL, while another table entry gives a minimum of 76 ng/mL. The inconsistency should remain visible rather than be converted into a single exact lower boundary. The series still demonstrates measurable metabolite in this alternative specimen.

The method used blood calibrators for chest fluid. The paper described calibration from 1 to 1000 ng/mL for fluids and a 1 ng/mL quantitation limit, with identification criteria including retention-time agreement within 0.05 minutes and ion-ratio agreement within 20%. It also described testing tenfold and hundredfold dilution. These method descriptions do not amount to a fully independent, matrix-matched validation for every possible decomposed cavity specimen.

Hydrolysis made some cross-specimen comparisons different

Chest fluid and preserved blood were prepared without hydrolysis. Urine, bile and gastric contents underwent alkaline hydrolysis before extraction. A hydrolyzed result can include analyte released from conjugated forms, so it does not necessarily measure the same fraction as an untreated specimen.

Consequently, a concentration difference cannot be attributed solely to anatomical distribution. Preparation also matters. This issue is illustrated separately by hydrolyzed urine and bile cannabinoid measurements after death.

The report contains inconsistent summaries of cavity-fluid ratios to other specimens. They do not provide a dependable divisor for estimating blood from a new chest-fluid value. Blood-site differences, small denominators and unequal preparation further limit such a conversion.

Decomposition was associated descriptively with higher values

Median cavity-fluid THC-COOH was 240 ng/mL in the five non-putrefied cases, 642 ng/mL in the three partially putrefied cases and 1100 ng/mL in the seven heavily decomposed cases. These are small descriptive groups. The paper did not supply a formal statistical test establishing the decomposition-stage pattern.

The authors proposed release from surrounding tissues, contamination, deconjugation and other postmortem changes as possible explanations. The study did not directly trace the source of the metabolite or measure each person’s concentration before death. It therefore cannot determine how much of an individual cavity-fluid result arose through a particular postmortem mechanism.

The authors also reported no significant relationship with the available drug-use history and no concentration difference by body mass index. These negative findings do not establish precise timing or exclude effects that a small selected sample could miss.

What the finding does not prove

THC-COOH is a metabolite finding, not a direct measure of psychoactive effect. Its detection cannot establish recent impairment, a consumed dose, or that cannabis caused the death. Absence of parent THC in cavity fluid likewise does not exclude prior cannabis exposure.

The useful inference is narrower: this fluid can preserve detectable metabolite under the studied circumstances. The specimen’s location, decomposition, preparation and calibration must accompany the result. Other alternative matrices, including muscle tested for THC and CBD, likewise require analyte-specific interpretation rather than automatic substitution for blood.

Primary source

Zughaibi TA, Alharbi H, Al-Saadi A, Alzahrani AE, Al-Asmari AI. 11-Nor-9-Carboxy Tetrahydrocannabinol Distribution in Fluid from the Chest Cavity in Cannabis-Related Post-Mortem Cases. Toxics. 2023;11:740. doi:10.3390/toxics11090740.

Diluting postmortem bile can improve drug analysis by reducing interference from the specimen itself. In a 108-target LC–MS/MS study, 1:100 dilution performed better than undiluted bile or 1:10 dilution. Yet the authors still identified problematic suppression for buprenorphine and THC-COOH. The headline target count therefore did not mean every compound had equally satisfactory performance.

Why dilution was part of the method

Franzin and colleagues developed a bile method covering drugs and metabolites across several classes. They compared pure bile with bile diluted in phosphate-buffered saline at 1:10 and 1:100. Pure bile created analytical difficulties, while 1:100 reduced matrix effects relative to 1:10 and retained sufficient sensitivity for low-concentration analytes.

Dilution trades reduced matrix burden against reduced analyte signal. Its success depends on the complete procedure and the compound being measured. The study does not establish 1:100 as the preferred dilution for every bile assay, instrument or target.

Calibrators and controls came from a commercial lyophilized mixture reconstituted in the matrix under evaluation. The procedure used 50 µL of sample, internal standards and beta-glucuronidase, with two hours of incubation at 45°C before protein precipitation. It did not require solid-phase extraction.

The result depended on preparation and calibration

Enzymatic deconjugation changes what can contribute to the measured analyte signal. A result from this hydrolyzed preparation should not be treated automatically as the free-analyte concentration from an untreated specimen. The dilution and calibration basis also need to remain attached to any numerical report.

The main paper displayed detailed performance for 12 representative compounds, with additional analyte-level information assigned to supplementary material. Its main-table findings should not be expanded into independently checked performance claims for all 108 targets.

For the displayed validation, calibration correlations exceeded R² = 0.99. Accuracy and precision used three control levels tested three times within a day and in three different runs. Reported precision was no greater than 15%, with accuracy within 100 ± 15% of target. Six blank bile specimens were used to investigate selectivity.

Table 2 reported morphine detection and quantitation limits of 0.21 and 1.08 µg/L, respectively, and methadone limits of 4.55 and 28.50 µg/L. These are different analytical endpoints and belong to this stated preparation and calibration. They are not blood concentrations or toxicity thresholds, and they should not be multiplied again by a dilution factor without establishing the reporting basis.

Two compounds remained important exceptions

The authors identified matrix suppression for buprenorphine and 11-nor-9-carboxy-THC, usually called THC-COOH, and concluded that the method was not ideal for these targets. A general statement about satisfactory bile performance therefore needs this qualification.

Internal standards and a sensitive mass spectrometer do not eliminate the need for target-specific validation. Suppression concerns analytical response; it is not proof of drug degradation in the body. Nor does poor performance for two targets invalidate every other measurement in the panel.

What the 13-case application demonstrated

The method was applied to specimens from 13 forensic individuals with suspected intoxication or overdose. Blood came from the femoral vein; urine and bile were also collected at autopsy. Leftover specimens were stored at −20°C. The report did not establish a uniform death-to-collection interval.

All prepared case samples had been positive on initial immunoassay screening. This selected application therefore cannot establish sensitivity among all screen-negative deaths or population drug prevalence. The paper also gives inconsistent drug-frequency percentages across its abstract and results; those percentages should not be treated as a reconciled prevalence estimate.

Its reported frozen stability concerned diluted-bile quality controls tested after one week and one month at −20°C, with supporting results described as unchanged but not displayed. This does not demonstrate stability in a decomposing body, at room temperature, or through repeated freezing and thawing.

What a bile concentration can support

This work supports a specified quantitative preparation with explicit target limitations. It does not validate conversion of bile into an antemortem blood concentration or determine impairment or cause of death from a positive result.

A later, separate study evaluated qualitative bile immunoassay agreement with confirmation. That screening question differs from whether this diluted LC–MS/MS procedure accurately quantifies a particular compound. Keep both questions separate when reviewing a case.

Primary source

Franzin M, Ruoso R, Peruch M, Stocco G, D’Errico S, Addobbati R. Quantification of 108 illicit drugs and metabolites in bile matrix by LC–MS/MS for the toxicological testing of sudden death cases. Archives of Toxicology. 2024;98:135–149. doi:10.1007/s00204-023-03631-z.

An assay that measures 82 drugs does not have identical quantitative performance for all 82, nor does validation in living-person whole blood automatically establish performance in every autopsy specimen. Steuer and colleagues’ multianalyte LC–MS/MS study reported six analyte exceptions and a specifically limited postmortem matrix assessment. Those details are more useful than the panel size alone when reviewing a result.

What the method was designed to do

The investigators developed a quantitative method using 200 µL of whole blood, protein precipitation, internal standards and an 18.5-minute LC–MS/MS run. Two multiple-reaction-monitoring transitions were acquired for each target. This was a defined targeted panel, rather than an unrestricted search for every possible toxicant.

Development and validation included blood from ten healthy volunteers and ten urine specimens. Ten previously drug-negative postmortem blood specimens were additionally examined for selectivity and matrix effects. Samples were stored at −20°C before their use in development or validation.

The paper did not provide one uniform postmortem blood collection site or death-to-collection interval. The autopsy specimens did not show severe putrefaction by the available case information or visual assessment. The experiment therefore should not be represented as comprehensive validation across heavily decomposed blood.

Which quantitative criteria had exceptions?

Using the selected internal standards and calibration models, 76 compounds met the specified bias and imprecision criteria: below 15%, or below 20% for the low quality-control level. Exceptions were buprenorphine, norclobazam, clonazepam, N-desalkylflurazepam, lormetazepam and triazolam.

The failures were level-specific. Buprenorphine failed the bias criterion in the above-calibration-range dilution experiment. The five benzodiazepines had bias outside the criterion at one of four quality-control levels. This is different from saying that every concentration for those compounds was unusable, or that the other 76 had failed.

Clonazepam illustrates why the table matters: at the low control concentration of 6 µg/L, bias was −25.7% and interday imprecision was 23.9%. A listed quantitation limit does not erase an observed failure at a tested control level. Review the relevant analyte and concentration, rather than relying only on the abstract’s general description.

What was tested in postmortem blood?

Postmortem selectivity and matrix-effect testing addressed interference and changes in instrument response. It did not repeat the entire living-blood quantitative validation at every concentration. The matrix-effect comparison used a medium quality-control level.

Across analytes, postmortem blood produced a mean additional suppression effect of 29% relative to living-person blood. This is an average instrument-response comparison, not evidence that 29% of a drug disappeared from a body or that every reported concentration should receive a 29% correction.

Internal-standard correction produced high reproducibility for all compounds in the tested postmortem specimens. That is useful evidence for this procedure and sample set. It does not establish equal absolute signal, successful performance in all decomposed specimens, or an unlimited ability to transfer the method to other matrices. A related benzodiazepine study using whole-blood calibration in autopsy tissues likewise shows why matrix-specific performance needs examination.

Detection limits and stability answer narrower questions

The method adopted analyte-specific lower quantitation limits from its calibration ranges. The authors did not systematically investigate limits of detection. A quantitation limit should therefore not be relabeled a separately established detection limit, and a negative panel result cannot exclude substances outside the panel.

Stability testing concerned processed extracts. Some absolute peak areas fell by more than 25% after 36 hours, while analyte-to-internal-standard ratios remained stable for 72 hours. This distinction concerns prepared material awaiting analysis. It does not demonstrate unchanged drug concentrations inside a body over a 72-hour postmortem interval.

How to assess an actual autopsy report

Identify the compound, quantitative range, control level, calibration model, dilution history and specimen condition. Check whether the reported number lies in a portion of the procedure supported by satisfactory performance. A mass-spectrometric identification and an accurately quantified concentration are related but separate claims.

Even a well-supported quantitative result does not alone establish dose, impairment, cause of death or the amount of postmortem redistribution. This study validates analytical operations within stated limits; it does not validate those broader biological inferences.

Primary source

Steuer AE, Keller M, Kraemer T, Poetzsch SN. Multianalyte Approach—Including Automated Preparation of Calibrators—for Validated Quantification of 82 Drugs in Whole Blood by Liquid Chromatography–Tandem Mass Spectrometry. Drug Testing and Analysis. 2025;17:954–988. doi:10.1002/dta.3794.

The designer-benzodiazepine concentrations reported in 21 Norwegian autopsies were descriptive findings, not established lethal ranges. Heide and colleagues explicitly lacked the causes of death for those cases. Their separate evidence about impairment came from living people and cannot be transferred directly to a decedent’s autopsy blood.

Separate the 21 autopsies from the 554 living cases

The study included 575 positive forensic cases submitted between 1 June 2016 and 30 September 2019: 554 living cases involving suspected impaired driving or other offenses, and 21 medicolegal autopsies. Flualprazolam entered the analytical repertoire only in December 2018, so its observation period was shorter.

The living-case concentration summary in Table II is not the autopsy dataset. For example, its 334 diclazepam findings and median of 0.0096 mg/L describe living cases. Table IV separately reports 13 autopsy diclazepam findings, with a median of 0.0032 mg/L.

The autopsy specimens were femoral venous whole blood collected into 25 mL polystyrene tubes containing 0.3 mL of 67% weight/volume potassium fluoride solution. Living blood used 5 mL glass tubes containing 20 mg sodium fluoride and 143 IU heparin. Samples were refrigerated at 4°C for up to two weeks while analyses were completed. Those handling descriptions do not establish analyte stability, and the paper did not provide a uniform postmortem collection interval.

What the autopsy table actually reported

Drug	Autopsy findings	Median, mg/L	Reported range, mg/L
Diclazepam	13	0.0032	0.0018–0.032
Etizolam	2	0.026	0.022–0.029
Flubromazolam	1	Single value: 0.052	Not a population range
Phenazepam	5	0.0059	0.0051–0.052

Clonazolam, flualprazolam and flubromazepam were not detected in these autopsies. That absence in this small, selected series does not establish their absence from other deaths or a universal laboratory detection capability.

Other drugs were detected in 20 of the 21 cases. Phenazepam was the only detected drug in one case. Because the investigators did not know the causes of death, even that single-drug finding cannot be described from this paper as a proven phenazepam fatality.

Quantitative methods still had defined reporting limits

Blood screening used UHPLC–MS/MS, followed by quantitative confirmation using a different chromatographic procedure. Methods and instrumentation changed during the study. Duplicate analyses and independent quality controls supported the reported quantitative results.

The stated reporting cutoffs included 0.0016 mg/L for diclazepam, 0.014 mg/L for etizolam, 0.00037 mg/L for flubromazolam and 0.0017 mg/L for phenazepam. These analytical cutoffs were at or above the respective quantitation limits. They are not concentrations at which impairment or death begins.

What the living-person impairment analysis added

In 25 living cases, one designer benzodiazepine was the only drug judged relevant to impairment. This definition allowed other detected drugs considered below relevant concentrations; it did not mean every specimen was chemically free of all other substances. Physicians judged 19 of these people impaired and six not impaired.

For the 16 diclazepam cases in that subgroup, the impaired-versus-not-impaired concentration comparison was not statistically significant, with p = 0.133. A separate analysis found a significant association between concentration and degree of impairment, with Spearman’s rho = 0.561 and p = 0.024. Both results matter: an association with an ordered clinical assessment does not create a sharp individual impairment threshold. Other compounds had too few such cases for statistical analysis.

Why the numbers cannot reconstruct the concentration during life

The study did not include paired antemortem and postmortem specimens to quantify concentration change. Blood-to-plasma ratios were also unknown for the seven designer benzodiazepines. A postmortem blood result therefore cannot simply be matched to a plasma effect range or treated as an earlier driving concentration.

Use the autopsy values as limited historical context with their small drug-specific denominators. They do not independently establish dose, impairment or cause of death. The broader limitations of comparing therapeutic plasma ranges with autopsy blood apply here as well.

Primary source

Heide G, Høiseth G, Middelkoop G, Øiestad ÅML. Blood Concentrations of Designer Benzodiazepines: Relation to Impairment and Findings in Forensic Cases. Journal of Analytical Toxicology. 2020;44:905–914. doi:10.1093/jat/bkaa043.